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Abstract Accumulating evidence from different lines of
research suggests an involvement of the immune system in
the pathophysiology of several psychiatric disorders. Dur-
ing recent years, a series of positron emission tomography
(PET) studies have been published using radioligands for
the translocator protein (TSPO) to study microglia activa-
tion in schizophrenia, bipolar I disorder, major depression,
autism spectrum disorder, and drug abuse. The results have
been somewhat conflicting, which could be due to differ-
ences both in patient sample characteristics and in PET
methods. In particular, further work is needed to address
both methodological and biological sources of variability
in TSPO levels, a process in which the use of animal
models and small animal PET systems can be a valuable
tool. Given this development, PET studies of immune
activation have the potential to further increase our
understanding of disease mechanisms in psychiatric dis-
orders, which is a requisite in the search for new treatment
approaches. Furthermore, molecular imaging could become
an important clinical tool for identifying specific subgroups
of patients or disease stages that would benefit from
treatment targeting the immune system.
Keywords Psychiatry  PET  Neuroinflammation 
Microglia  TSPO
The role of the immune system in psychiatric
disorders
The concept that the immune system may have a role in the
pathophysiology of psychiatric disorders has been dis-
cussed for several decades. Early observations in support of
this hypothesis include reports of psychotic symptoms in
autoimmune and infectious diseases engaging the central
nervous system (CNS) [1, 2]. Furthermore, studies in both
animals and humans show that immune activation can
induce depressive-like symptoms, as part of what is com-
monly referred to as the ‘‘sickness behaviour’’ syndrome
[3, 4].
With regard to studies in psychiatric populations, initial
epidemiological observations of increased incidence rates
of schizophrenia for cohorts born after influenza epidemics
[5] have been followed up by a series of studies showing
that infections during gestation or in early life lead to an
increased risk of developing psychotic disorders [6]. In
addition, autoimmune diseases and infections have been
associated with mood disorders [7]. In support of a role for
genetically determined alterations in the immune system in
schizophrenia, a recent large-scale genome-wide associa-
tion study found that associations were enriched for genes
related to immune function [8]. Effects of genes related to
immune function have also been found for depression,
bipolar disorder, and autism [9, 10]. Furthermore, phar-
macoepidemiological studies have suggested that anti-in-
flammatory drugs, such as non-steroidal anti-inflammatory
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Although the genetic and epidemiological data strongly
suggest that immune function has a role in the development
of psychiatric disease, an important question from a clini-
cal perspective is if there are also ongoing brain immune
disturbances in patients.
Post-mortem studies have shown increases in microglia
in patients with schizophrenia [12, 13], autism [14], and
cocaine abuse [15]. However, the post-mortem results may
differ from the brain immune situation in vivo and in
general there is a large delay between disease onset and
post-mortem assessment. Studies on immune markers in
blood, such as cytokines, have shown increased levels in
both first-episode and chronic schizophrenia [16, 17] as
well as in depression [18] and autism [19]. Similarly, gene
expression of immune-related proteins has shown to be
altered in schizophrenia and bipolar disorder [20]. How-
ever, findings have generally been inconsistent, with dif-
ferent markers showing effects in different studies, and
there is often a large degree of overlap between patients
and control subjects. Importantly, there is little direct
passage of cytokines between brain and periphery [21, 22],
and therefore, peripheral markers may not be representative
of CNS processes. Studies in cerebrospinal fluid (CSF) are
scarce, but alterations in immune markers have been shown
for schizophrenia [23, 24], bipolar disorder [25, 26], and at
least in a subgroup of patients with depression [27].
Although these studies are encouraging, a large degree of
inconsistency still remains. Furthermore, CSF analyses
cannot provide any anatomical information, and there is
thus a need for more direct measures of brain immune
activation in psychiatric patients.
Measuring brain immune function in vivo:
molecular imaging of TSPO
Molecular imaging is currently the only method to directly
examine brain biomarkers at a molecular level in vivo. Of
the available tools, positron emission tomography (PET) is
the most accurate method, whereas single-photon emission
computed tomography (SPECT) has been less prevalent
due to the lower sensitivity as well as limited temporal and
spatial resolution as compared to PET [28]. Thus far, all
PET studies assessing the immune system in psychiatric
populations have targeted the 18-kDa translocator protein
(TSPO), and this method is thus the focus of the present
review.
TSPO, formerly known as the peripheral benzodiazepine
receptor, is located in the outer mitochondrial membrane of
microglia and, to some extent, astrocytes. Although its
exact function remains unclear, TSPO has been described
to be involved in many physiological processes, including
cholesterol transport and steroid synthesis [29].
Importantly, microglia are considered to be the key cell
type involved in CNS immune processes, as they can be
activated by cytokines and additionally contribute further
to cytokine release [30]. Activation of resident microglia
and infiltration of macrophages contribute to neuronal
injury and synaptic damage [29], although neurotrophic
and protective functions have also been observed [31, 32].
TSPO is a widely used marker for immune activation in the
CNS, since a change in phenotype and functional state of
microglia is associated with increased TSPO expression
[30].
The PET radioligand (R)-[11C]PK11195 has been the
most commonly used PET tracer to assess TSPO in the
CNS. Several studies describe prolonged increased binding
in patients with stroke and traumatic brain injury which can
be seen as proof-of-concept studies [33, 34]. Since(R)-
[11C]PK11195 shows a high level of non-specific binding,
during the last decade significant efforts have been made to
develop new TSPO radioligands. Those that have hitherto
been applied to psychiatric conditions are [11C]DAA1106,
[18F]FEPPA, and [11C]PBR28 [35–40]. These second-
generation ligands are considered to have improved signal-
to-noise ratio compared to [11C]PK11195, based on a 7- to
60-fold higher affinity for TSPO and animal blocking
studies showing up to 80-fold higher specific binding than
[11C]PK11195 [36, 38, 40, 41]. A practical drawback with
all these novel compounds is their sensitivity to a poly-
morphism in the gene encoding TSPO, which leads to three
distinct binding classes: high-affinity binders (HABs; 49 %
of the Western population), mixed-affinity binders (MABs;
42 %), and low-affinity binders (LABs; 9 %) [13, 42]. As a
consequence, up to ten percentage of the population cannot
be part of clinical studies due to LABs. In the remaining
subjects, the effects of TSPO polymorphism require
genotyping the subjects and controlling for genotype in the
study design and analysis. Furthermore, second-generation
TSPO radioligands have thus far not been validated in
preclinical models to the same extent.
Psychiatric disorders and TSPO PET imaging:
clinical studies
We identified all PET studies that examined TSPO binding
in psychiatric disorders (Table 1). Thus far, schizophrenia
is the most studied condition with four articles, whereas
only one to two studies have been published for mood
disorders, autism spectrum disorder, and drug abuse.
Schizophrenia
The first study on TSPO in schizophrenia used the radi-
oligand (R)-[11C]PK11195 in ten patients and ten age-
450 Clin Transl Imaging (2015) 3:449–460
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matched healthy control subjects [43]. All patients were
examined within 5 years of disease onset, with an average
disease duration of 3.1 ± 1.7 years. (R)-[11C]PK11195
binding potential (BPP, as calculated with K1*k3/k2*k4)
values were calculated using a two-tissue compartment
model (2TCM) with metabolite-corrected plasma as input
function. Patients had mild symptoms at the time of PET
scanning as measured with the Positive and Negative
Syndrome Scale (PANSS), with average scores of 12 ± 3
and 14 ± 4 for symptoms, respectively, and they were all
on atypical antipsychotics. The authors observed an
increase in (R)-[11C]PK11195 binding potential in patients
in total grey matter, which was the only region analysed
(Table 1). No significant correlation between symptom
severity and total grey matter BPP was found.
Doorduin et al. [44] used (R)-[11C]PK11195 to examine
seven patients with schizophrenia with active psychosis,
defined by a score of 5 or more on 1 PANSS positive
symptom item or a score of 4 on 2 items, in comparison
with eight healthy volunteers. The disease duration ranged
Table 1 Overview of clinical TSPO PET studies in psychiatric disorders




Main findings Regions studied
Kenk et al.
[46]














Schizophrenia [11C]PK11195 8/7 2TCM BPND Increase in
hippocampus
















PC, OC, dPU, dCA,
VST, ACC, TH, insula
Hannestad
et al. [50]
Major depression [11C]PBR28 10/10 1TCM, 2TCM,
MA1 VT
No group differences TC, FC, PC, OC, CER,




Bipolar I disorder [11C]PK11195 11/14 2TCM BPND Increase in right
hippocampus
HIPP, TC, FC, DLPFC,






[11C]PK11195 20/20 SRTM BPND
Ref:
cerebellum**
Increase in all regions STC, fusiform cortex,




Cocaine abuse [11C]PBR28 17/15 2TCM VT No group differences MTL, DLPFC, MPFC,











Increase in all regions OC, insular cortex, TH,
ST, midbrain
1TCM one-tissue compartment model, 2TCM two-tissue compartment model,MA1 multilinear analysis, SRTM simplified reference tissue model,
BPND binding potential, VT total distribution volume, d dorsal/dorso, l lateral, m medial, o orbito, p pre, s superior, v ventral/ventro, ACC anterior
cingulate cortex, CA caudate, CER cerebellum, CC corpus callosum, FC frontal cortex, FP frontal pole, HIPP hippocampus, OC occipital cortex,
PC parietal cortex, PCC posterior cingulate cortex, PLIC posterior limb of the internal capsule, PU putamen, SLF superior longitudinal
fasciculus, ST striatum, TH thalamus, TC temporal cortex
* TSPO genotype was not accounted for
** Ref = reference tissue
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from 1 to 16 years (average 5.3 ± 5.6 years), with 1–4
experienced psychotic episodes. Patients had moderate
symptoms at the time of PET scanning, with average
PANSS scores of 20 ± 3, 17 ± 5, and 37 ± 7 for positive,
negative, and general subscales, respectively. All patients
were using antipsychotics, and the use of benzodiazepines
was allowed for 1–2 weeks prior to PET examinations.
Substance use and anti-inflammatory drugs were reported
as exclusion criteria. (R)-[11C]PK11195 binding potential
(BPND defined as k3/k4) was quantified using 2TCM. In
contrast to the study by van Berckel et al. [43], the (R)-
[11C]PK11195 binding potential of whole-brain grey mat-
ter was not found to be increased in patients compared to
control subjects. Multiple ROIs were examined (Table 1),
and a significant increased BPND was found in the hip-
pocampus of patients. To reduce the variation in the small
sample size, the data were normalised to the whole-brain
grey matter for statistical analysis which means that the
results are not directly comparable to the other TSPO
studies in schizophrenia.
Takano et al. [45] studied fourteen patients with chronic
schizophrenia and fourteen age- and sex-matched controls
with the second-generation tracer [11C]DAA1106. Patients
had a long disease duration (18.8 ± 12.2 years). All
patients were on antipsychotics, and benzodiazepines were
allowed for more than 1 month before the start of the
study. Substance and alcohol abuse were exclusion criteria.
All cortical grey matter regions were assessed, as well as
the striatum, and BPND as quantified using 2TCM was the
main outcome measure. Patients had moderate symptoms
at the time of PET scanning as scored on PANSS (total
score 78.6 ± 20.7). Although no significant differences in
TSPO levels between patients and controls were reported,
correlations were found between TSPO binding and disease
duration as well as positive symptoms. However, TSPO
genotype was not determined, and since in vitro studies
show fourfold differences in [11C]DAA1106 affinity
between MAB and HAB subjects [42], this significantly
limits the interpretation of the results.
Using [18F]FEPPA, Kenk et al. [46] examined grey
matter frontal and temporal ROIs, striatum, and white
matter ROIs in a sample of 16 patients (10 HABs and 6
MABs) and 27 controls (19 HABs and 8 MABs; Table 1).
The disease duration was 14.8 ± 8.8 years, and patients
had moderate symptoms at the time of PET scanning
(PANSS total 70.2 ± 9.7). Patients were on treatment with
either atypical or typical antipsychotics, and a minor pro-
portion were also using antidepressants or anti-Parkinso-
nian drugs. Benzodiazepine use was not allowed except for
clonazepam. Total distribution volumes (VT) values were
calculated using 2TCM with an arterial plasma input
function. Since [18F]FEPPA binding is also sensitive to
TSPO genotype, this factor was included in the statistical
analysis. No significant differences in VT values were
found between patients and controls in either white or grey
matter regions.
Clinical factors that might influence the study results are
patient characteristics such as disease duration, symptom
severity, and medication use. Both the two (R)-
[11C]PK11195 studies that found an effect had patients
with a shorter disease duration [43, 44], whereas no dif-
ference was reported in patients with a longer disease
duration [46]. This could indicate that microglia activation
has a more prominent role in early disease phases. How-
ever, in order to answer this question longitudinal studies
are necessary, ideally including also measurements in first-
episode patients and high-risk individuals. In addition,
patients had mild to moderate symptoms at the time of PET
scanning, and thus it is of interest to examine if more
severe pathology shows a greater increase in TSPO bind-
ing. Importantly, benzodiazepine use was an exclusion
criterion in all studies (except for clonazepam in one study
[46]) since most benzodiazepines have affinity for the
TSPO and can compete for binding with TSPO with the
PET tracer [47]. However, a recent study found that this
was mainly the case for the benzodiazepine diazepam in
higher doses [48]. Further studies should be performed to
confirm this observation, as alleviating this restriction
could potentially improve recruitment of more severely ill
patients.
One important limitation in all studies published thus far
is that all patients were on treatment with antipsychotic
drugs. Most antipsychotics, besides clozapine, tend to
decrease TSPO expression [49]. Although evidence from
in vivo human research is lacking, this suggests that there
might be an underestimation of the signal. For instance,
this could explain the negative findings in Kenk et al. [46].
Examination of drug-naive patients will be critical to
address this issue.
Mood disorders
To date, two studies assessed TSPO in patients with major
depressive disorder and one study examined bipolar I
patients (Table 1).
In the study by Hannestad et al. [50], [11C]PBR28 was
used to examine ten patients with major depression (MD)
and ten healthy controls. The sample included seven HABs
in both the patient group and control group, respectively.
Patients were allowed to take antidepressant medications if
the dose had been stable for at least 4 weeks (although it
was not reported how many patients were administered
antidepressants at the time of PET). Laboratory signs of
peripheral immune activation, as defined by elevated high-
sensitive C-reactive protein (CRP), were an exclusion cri-
terion. Symptom severity at the time of examination was
452 Clin Transl Imaging (2015) 3:449–460
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mild to moderate, with 19.7 ± 6.7 scores on the Mont-
gomery–A˚sberg Depression Rating Scale (MADRS, range
0–60; 0–6 normal, 7–19 mild, 20–34 moderate,[34 severe
depression [51]). This represented a significant reduction
from 25.6 ± 7.5 at screening. Groups were matched for
TSPO genotype. [11C]PBR28 VT values were calculated
using 1TCM, 2TCM, and the multilinear analysis MA1
[52], using the metabolite-corrected arterial plasma curve
as input function. In addition, VT corrected for plasma free
fraction (VT/fP) was determined. No significant differences
in binding were found in a selection of cortical ROIs, white
matter, and basal ganglia. Using VT/fP instead of VT did not
change these results.
Setiawan et al. [53] examined twenty MD patients (15
HABs, 5 MABs) and twenty healthy controls (14 HABs and
6 MABs) using [18F]FEPPA. All patients were medication-
free for at least 6 weeks prior to the PET examination.
Depressive symptoms were moderate to severe, with aver-
age scores of 20 ± 3.8 on the 17-item Hamilton Depression
Rating Scale (HDRS, range 0–52; 0–7 normal, 8–13 mild,
14–18 moderate, 19–22 severe, C23 very severe depression
[54]). [18F]FEPPA VT calculated using 2TCM was the main
outcome measure, and ROIs selected were prefrontal cortex,
anterior cingulate cortex (ACC), and insula. Genotype was
included as a factor in the statistical analysis. A global effect
of diagnosis on [18F]FEPPA VT was shown, with higher
values in patients in all regions examined. Furthermore,
HDRS scores were positively correlated with TSPO VT in
the ACC, after correcting for genotype. Serum markers for
neuroinflammation were measured, but there were no cor-
relations with brain TSPO levels.
Haarman et al. [55] studied fourteen bipolar I patients
compared to eleven healthy volunteers. All patients except
one were euthymic, and the disease duration ranged from 2
to 37 years (average 25.6 ± 12.0 years). All patients had
experienced multiple depressive and hypomanic or manic
episodes. All except one patient were on mood-stabilising
medication. (R)-[11C]PK11195 BPND was quantified using
2TCM with plasma input function. Multiple brain regions
were analysed, although hippocampus was selected as the
main ROI, based on human and preclinical evidence sug-
gesting that this region could be a particular focus of
microglia activation. For the statistical analysis, binding in
whole-brain grey matter was used as a covariate to reduce
the between-subject variation. Whereas BPND in the whole-
brain was not different between patients and healthy vol-
unteers, higher values were observed in the right hip-
pocampus of bipolar I patients.
The differences in clinical factors between the mood
disorder studies make it difficult to compare the PET out-
come. In the two studies on depression, the study of Seti-
awan et al. [53] had a significantly larger sample size, and
patients had more severe symptoms than in the study of
Hannestad et al. [50], which might explain the difference in
results. A further difference is the exclusion of signs of
mild peripheral immune activation in the latter study. Since
CRP has shown to be elevated in patients in depression
[56], suggesting that peripheral immune activation is
related to the disease mechanism, this could have led to a
selection bias towards patients with relatively low levels of
immune activation.
Furthermore, in two of the studies the patients were on
treatment with mood-stabilising medication [50, 55],
whereas in the study by Setiawan [53], patients were
medication-free for 6 weeks. Most mood-stabilising med-
ications tend to decrease TSPO expression [57, 58], which
suggests an underestimation of the signal in the patients
who were assigned to treatment, although this has to be
confirmed in future studies with medication-naı¨ve patients.
Developmental disorders
To date, only one PET study has assessed TSPO binding in
patients with developmental disorders. In the study by
Suzuki et al. [59], (R)-[11C]PK11195 was used to examine
twenty individuals with autism spectrum disorder and
twenty age- and intelligence quotient (IQ)-matched con-
trols. Patients were young adults in an age range from 18.6
to 31.9 (average 23.3 ± 4.0) years, had IQ scores above 80
(average 95.9 ± 16.7), and did not receive any medication.
Arterial blood was not sampled; instead, (R)-[11C]PK11195
BPND was quantified using a reference tissue approach. A
normalised input curve based on the averaged TACs from
the ROIs placed over the cerebellar cortices in the control
group was used for both the control and the patient data
analysis. In the ROI-based analysis, an overall statistical
effect was shown, and increased (R)-[11C]PK11195 bind-
ing potential was reported in all examined regions,
including (subparts of) the cerebellum, ACC, corpus cal-
losum, and frontal, temporal, and parietal cortex (Table 1).
These results were confirmed in a voxel-based analysis.
There were no correlations between TSPO BPND and
clinical symptoms levels. As discussed below, the refer-
ence tissue approach used in the study limits the conclu-
sions that can be drawn.
Substance use disorders and the potential confound
of drug use
Two PET studies examined TSPO in substance use disor-
ders (Table 1). Sekine et al. [60] used (R)-[11C]PK11195 to
examine twelve methamphetamine abusers in comparison
with twelve healthy volunteers. The disease duration of the
patients ranged from 1 to 12 years (average
6.8 ± 3.9 years); however, patients were abstinent on
average almost 2 years prior to PET examinations. A
Clin Transl Imaging (2015) 3:449–460 453
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modified version of the Drug Effect Rating Scale was used
to assess the scale for methamphetamine craving. Scores
were in a range from 1 (no craving) to 10 (most intense
craving) with an average score of 4.9 ± 3.4. PET data were
analysed with a reference tissue approach, whereby aver-
aged TACs from the frontal, parietal, and occipital cortices
from the control group were used for both the control and
the patient data analysis. Significantly higher BPND values
were found in methamphetamine abusers in all ROIs
studied, with differences ranging from 3- to 15-fold. A
significant negative correlation was found between (R)-
[11C]PK11195 BPND and the duration of methamphetamine
abstinence in midbrain, thalamus, and striatum, suggesting
that microglial function can be normalised by protracted
abstinence.
In the study by Narendran et al. [61], 15 chronic cocaine
abusers (8 HABs, 5 MABs, 2 LABs) and seventeen healthy
controls (12 HABs, 4 MABs, 1 LAB) were examined using
[11C]PBR28. Patients were on average 39.9 ± 9.0 years
old and had been smoking crack cocaine for an average of
17 ± 7 years. Patients had a minimum of 2 weeks outpa-
tient abstinence as monitored with urine toxicology and did
not receive medication. VT values were calculated in a
standard manner, using 2TCM with an arterial plasma input
function, and data were corrected for TSPO genotype. No
differences in [11C]PBR28 VT were observed between
patients and control subjects, as assessed in both cortical
and subcortical brain regions.
Thus, these two studies differ markedly in their findings.
However, apart from the fact that different drugs of abuse
were studied, a direct comparison is precluded since there
are major differences in both the clinical status of patients,
such as time of abstinence, and methodology—in particu-
lar, the use of a reference region in the study by Sekine
et al. (see below for discussion).
For most psychiatric patients groups, there is an
increased prevalence of substance use disorders, such as
alcohol, cannabis, and nicotine use [62]. For instance,
cannabis is considered to be the most commonly used
illegal drug of abuse among patients with bipolar disorder
and schizophrenia [63, 64]. Although substance use dis-
order was an exclusion criterion in all studies, it cannot be
excluded that patients had a higher recreational use of
drugs of abuse. In most studies, actual drug use was
assessed with urine analysis [43, 46, 50, 53, 60, 61].
However, only four of the studies reported on or controlled
for smoking status, of which one study included only non-
smokers [53], one study reported only three smokers in the
patient group [50], one study allowed smoking and mat-
ched patients and controls for nicotine smoking status [61],
and one study did not include subjects that fulfilled nico-
tine-related DSM-IV criteria [60]. Importantly, in vitro
studies have shown that cannabinoids and nicotine have a
suppressant effect on the immune system [65, 66].
Although these observations remain to be confirmed
in vivo, the use of these common drugs of abuse could thus
theoretically diminish differences in TSPO levels between
patients and control subjects, which might in some cases
contribute to negative findings. In contrast, if an effect of
psychostimulants in TSPO levels even after long absti-
nence intervals can be confirmed, group differences in the
use of this drug could confound the results in the other
direction.
Preclinical studies of TSPO and psychiatric
disorders
Animal models and microglia activation
As psychiatric disorders are complex human disorders of
which the aetiology and the exact pathophysiology are
unknown, the three criteria commonly used for the vali-
dation of an animal model, i.e. face, construct, and pre-
dictive validity [67], cannot be fulfilled by a single animal
model. Animal models of psychiatric disorders do there-
fore only manifest certain aspects that can be translated to
the human disease, i.e. endophenotypes, such as hyper-
locomotion, anxiety, or deficits in prepulse inhibition.
With regard to the role of the immune systems in psy-
chiatric disorders, many animal models have linked psy-
chotic- and depressive-like behaviour to inflammatory
processes. For instance, modelling effects of maternal
immune activation on the risk of developing schizophre-
nia, viral infection of pregnant dams resulted in psy-
chotic-like symptoms in the offspring, and also microglia
were found to be activated [68, 69]. The bacterial endo-
toxin lipopolysaccharide (LPS) is often used to induce
depressive-like behaviour in rodents, leading to immedi-
ate sickness behaviour followed by behavioural deficits
that can be linked to depression [70, 71]. Importantly,
LPS has been shown to induce an activation of microglia,
lasting several days, as detected using immunohisto-
chemistry [72]. Conversely, animal models for stress-in-
duced depression have shown to induce both depressive
behaviour and microglia activation [73].
Preclinical TSPO PET imaging
With the advent of small animal PET systems, it has
become feasible to estimate TSPO levels in rats and mice,
thus enabling a translational approach (Fig. 1). Thus far,
only a few studies have assessed TSPO in animal models of
psychiatric disorders. Herpes virus-induced psychotic-like
behaviour in rats was found to be accompanied by micro-
glia activation, as shown with (R)-[11C]PK11195 PET [74].
454 Clin Transl Imaging (2015) 3:449–460
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(R)-[11C]PK11195 uptake was found to increase with the
increased severity of psychotic-like behaviour, and psy-
chotic-like behaviour and microglia activation could be
reduced by antipsychotic treatment. Dobos et al. [75] used
(R)-[11C]PK11195 PET to show microglia activation and
depressive-like behaviour following intracerebral LPS
injection in mice. Recently, LPS-induced systemic
inflammation in baboons was shown to induce an activa-
tion of microglia, as shown with [11C]PBR28 PET [76]. A
robust increase in TSPO binding was observed at 1 and 4 h
after intravenous injection of LPS. Depressive-like beha-
viour was not assessed in this study.
Methodological considerations
Taken together, the data thus far suggest a modest eleva-
tion of TSPO in psychiatric disorders. In general, the
increase was found throughout the entire brain, although
some studies reported a more focal elevation. However,
almost half of the studies did not find a difference between
patients and control subjects. Importantly, the results of the
TSPO PET studies are in many instances difficult to
compare, not only due to differences in patient character-
istics as discussed above, but also since the methods differ
in many aspects. In the following, we discuss some key
methodological points of relevance for interpreting the
findings.
The gold standard for TSPO PET quantification is to
apply a 2TCM, using a metabolite-corrected plasma input
function to estimate the contribution of free and non-
specific binding to the brain signal. The outcome parameter
of choice using this approach is VT, since the direct esti-
mation of BP, for instance, by calculating k3/k4 is less
reliable. Therefore, to facilitate comparisons between the
studies, it would have been useful if the studies with BP as
outcome parameter had additionally reported VT values.
Plasma input models are considered to have a high
variability, which may be due to methodological issues in
measuring the metabolite-corrected plasma input curve. In
order to reduce variability of plasma input models, several
approaches have been proposed.
Fig. 1 Cross-species TSPO
imaging using [11C]PBR28:
SUV images of a mouse b rat,
and c a healthy human subject.
All PET images are overlaid
over MR images. Courtesy of
the PET centre, Karolinska
Institutet
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In two of the studies reviewed above, normalisation of
regional values to whole-brain binding was performed [44,
55]. Although this reduces the variance, the drawback with
this approach is that it may underestimate true specific
binding, especially in case of a global increase. Further-
more, the whole cortex cannot be analysed using this
approach.
Reference tissue approaches, such as simplified reference
tissue method (SRTM) [77] and Logan DVR [78], are in
general preferred above plasma input models if a reference
region can be identified, both to reduce noise aswell as from a
practical perspective since arterial sampling can then be
eliminated.Thismaybeparticularly important for psychiatric
patient groups. One method is to use ratios of standardised
uptake values, which was recently reported to be more sen-
sitive than VT to detect TSPO elevations in Alzheimer’s dis-
ease for [11C]PBR28, with cerebellum as reference region
[79]. However, the use of this method assumes a very focal
TSPO elevation, which might not be the case for most psy-
chiatric disorders, and is sensitive to bias induced by differ-
ence in blood flow between regions and between groups.
In general, all reference tissue approaches are problem-
atic in TSPO PET studies as there is no anatomical region in
the brain devoid of TSPO.Whereas this protein was initially
not thought to be present in the non-diseased brain, wide-
spread (R)-[11C]PK11195 BPND increase was found in
healthy ageing [80]. In addition, specific binding to TSPO in
healthy individuals was recently confirmed in a TSPO
blocking study [81]. In the studies on autism and metham-
phetamine use by Suzuki et al. [59] and Sekine et al. [60],
normalised average time activity curves (TACs) from the
control group were used for both patient and control data,
which is not according to convention for reference tissue
approaches and creates further problems. In this case, group
differences in radioligand delivery and non-displaceable
binding are not taken into account, which might generate
artificially high BPND values in patients, and the results
therefore have to be interpreted with caution.
An alternative approach to identifying a reference ‘‘re-
gion’’ is to identify voxels with low specific binding based
on the shape of the TAC using supervised cluster analysis.
Several methods have been published for this purpose, and
they show reliable results in normal ageing and after
traumatic brain injury, both conditions leading to robust
microglia activation [80, 82]. However, the validity of
voxels devoid of TSPO can be questioned as for anatomical
reference regions, and this method might underestimate the
signal in comparison with other approaches [83]. Another
method to eliminate the need for arterial blood sampling is
to use an image derived input function, by extracting time-
activity curves from PET voxels corresponding to blood
vessels. This approach has been validated for tracers such
as [11C] flumazenil and [11C] AZ10419369 [84], and
preliminary data has shown feasibility for this method to
quantify [11C]PBR28 using HRRT [85]. So far, neither of
these approaches have been used to study psychiatric
populations.
General comments and future directions
It is well established that immune activation generally has a
negative effect on psychological well-being and may con-
tribute to both psychotic and depressive symptoms. A role
for immune-related processes as part of specific, causative
disease mechanisms in psychiatric disorders is at present
more uncertain. For schizophrenia and autism, both genetic
and epidemiological associations to immune function could
reflect a role for immunological factors affecting neurode-
velopment, which, for instance, is in line with recent obser-
vations suggesting that microglia are involved in synaptic
pruning as well as providing trophic support for neuronal
growth [32]. An alternative interpretation of these early
effects is the ‘‘sensitisation’’ theory, postulating that early
immune challenges to a genetically vulnerable system lead to
an increased inflammatory response later in life [86]. Even
so, the changes in psychiatric disorders are likely to be more
subtle than for classic CNS autoimmune disorders such as
multiple sclerosis (MS) and systemic lupus erythematosus
(SLE), as there are no radiological signs and the changes in
CSF and blood are less distinct. Since the immune system
can in certain instances even be regarded as neuroprotective
[31], immune dysregulation in psychiatric disorders may
even be conceived as an imbalance rather than a ‘‘one-di-
mensional’’ immune response.
Given these proposed more subtle immune changes in
psychiatric disorders, a major challenge for clinical TSPO
PET studies is the large degree of variability even in healthy
individuals. This is true irrespective of the radioligand and
methods of quantification used. In the studies reviewed
above, where variability was reported, the overall %
covariance (COV) was around 35 % for second-generation
radioligands across genotypes, and 25 % for (R)-
[11C]PK11195. With regard to interindividual variability,
this has shown to be moderate to high for both (R)-
[11C]PK11195 [87] and [11C]PBR28 [88, 89], whereas
reproducibility has not been assessed for any other TSPO
radioligands. Although part of this variability may be due to
methodological noise as discussed above, there may also be
biological explanations. For instance, in Collste et al. [89]
diurnal effects were shown on GM VT values, indicating
that part of the variability could be due to natural fluctua-
tions in the immune system in health. The variability in
TSPO levels has important implications in terms of the
sample samples needed, both for group comparisons and for
longitudinal studies. For instance, in the study on
456 Clin Transl Imaging (2015) 3:449–460
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schizophrenia by Kenk et al. [46] based on mean and
variability of VT values, it was calculated that 21 subjects
per group was required to detect a 20 % difference
(a = 0.05 and power = 0.8), which can be compared to the
16 % increase in [3H]PBR28 shown in a post-mortem study
[13]. If similar effects are expected in other disorders, most
studies performed thus far may have been underpowered.
Sample size may be particularly critical for studies using
second-generation radioligands, since accounting for TSPO
genotype in the analysis reduces statistical degrees of
freedom. To enhance the sensitivity of TSPO PET, an
important direction of research will be not only to reduce
methodological noise by finding reliable alternatives to
arterial sampling, but also to identify the physiological
factors that may influence TSPO levels in brain.
One important limitation for PET TSPO studies in
general is the lack of specificity of this marker. For
instance, TSPO is present also in astrocytes, which could
contribute to the signal [90, 91], and although both cell
types contribute to immune response, the specific type of
cell may have implications in terms of treatment. Fur-
thermore, for the microglia population, TSPO cannot dis-
tinguish between pro-inflammatory (M1) and protective
(M2) subpopulations. Thus, it will also be crucial to
developing tracers for other, more specific microglia
markers that are also sensitive to the functional phenotype.
Importantly, PET data then need to be combined with other
measures of immune function in order to fully reflect the
immunological status for each disease condition. Although
TSPO levels were compared to serum markers of inflam-
mation in some studies reviewed above, ideally this com-
parison should be done using CFS samples which more
closely reflect the state of the CNS immune system.
A crucial aim for research on the immune system in
psychiatry is to inform new treatment strategies. In
schizophrenia, depression, and autism, randomised con-
trolled studies have shown that the addition of cyclooxy-
genase (COX)-2 inhibitors to antipsychotics and
antidepressants treatment may lead to amelioration of
symptoms [92–94], although negative results have also
been reported [95]. In psychosis, both the COX inhibitor
aspirin and the broad-spectrum tetracycline antibiotic
minocycline, which directly attenuates microglia activa-
tion, have shown to reduce symptoms [96, 97]. However,
the immune hypothesis of psychiatric disorders would
implicate a need for drugs specifically directed towards
causative mechanisms. Molecular imaging is an important
tool towards this goal, as it allows for non-invasive studies
in both patients and animal models. Thus, immune markers
can be followed over time, allowing for monitoring of
disease progress and treatment effect. For instance,
[11C]PBR28 PET was recently used to detect effects of
immune-targeted treatment in Parkinson’s disease [98].
Furthermore, due to the translational nature of PET, clini-
cal studies can be supported by preclinical experiments,
also allowing for validation with post-mortem techniques
such as immunohistochemistry. For many psychiatric dis-
orders where large clinical trials have suffered from neg-
ative findings, these approaches could be critical towards
revitalising drug development programmes.
With increasing understanding of the biological pro-
cesses as well as methodological refinement, PET studies
of the immune system promise to be an important tool also
for clinical use. An important task will be to aid diagnosis
and potentially identify specific subgroups of psychiatric
patients in need of immune-targeting treatment. For
instance, a proportion of patients with schizophrenia show
auto-antibodies for neural receptors, suggesting that these
patients may constitute a subgroup in specific need of
treatment targeted against the immune system [99]. In
depression, specific subgroups of patients were shown to
respond to anti-TNF treatment [100]. Importantly, such
PET markers may prove to be specific for particular
pathophysiological mechanisms and symptom dimensions,
rather than reflecting current disease classifications
according to DSM.
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